German SME supplying synthetic hydrogel matrices and bioinks for 3D organoid culture, bioprinting, and tissue engineering research.
Cellendes develops synthetic hydrogel matrices and bioinks for three-dimensional cell culture, providing the biomaterial scaffolds in which cells grow, self-organize, and form tissue-like structures. Their core product is tunable PEG-based hydrogels that mimic the extracellular matrix, enabling researchers to culture organoids and stem cell-derived tissues under controlled mechanical and biochemical conditions. In EU projects they serve as the specialist biomaterials supplier, contributing validated hydrogel formulations that other consortium partners use for imaging, bioprinting, or cell therapy applications. Their work bridges material science and biology, making them a critical link between laboratory models and clinically relevant tissue constructs.
Hydrogel and bioink keywords appear in both LSFM4LIFE (organoid matrix) and BRIGHTER (bioprinting substrate), confirming this as the company's foundational capability across both projects.
BRIGHTER (2019–2022) focused specifically on bioprinting by light-sheet lithography, with Cellendes contributing bioink and hydrogel formulations for engineering skin models and complex tissues.
LSFM4LIFE (2016–2019) involved production of pancreatic organoids from progenitor stem cells for type 1 diabetes cell therapy, with Cellendes supplying the 3D matrix environment.
LSFM4LIFE targeted endocrine cell production for type 1 diabetes treatment, positioning Cellendes' hydrogels as an enabling material for cell therapy and regenerative medicine pipelines.
BRIGHTER combined high-speed, high-resolution bioprinting with skin model development, suggesting Cellendes is positioning its bioinks for in vitro screening applications beyond basic research.
In their early H2020 work (2016–2019), Cellendes contributed hydrogel matrices primarily as a research tool — providing the 3D environment needed to grow pancreatic organoids and study stem cell differentiation for type 1 diabetes. The focus was on biology: cell types, disease models, and therapeutic outcomes, with their material playing a supporting role. By 2019–2022, the emphasis had shifted decisively toward the material itself as the product: bioink formulations, printability, resolution, and speed in biofabrication workflows, with skin tissue engineering as the application. This trajectory suggests Cellendes is moving from being a reagent supplier for biologists toward being a precision materials company for the bioprinting industry.
Cellendes is clearly positioning itself as a bioink and biofabrication materials specialist, making them a natural partner for consortia working on organ-on-chip, skin equivalents, high-throughput drug testing models, or any project that needs tunable, printable hydrogel scaffolds.
Cellendes has participated exclusively as a consortium partner rather than a project coordinator, indicating they enter projects as a specialist supplier rather than a project driver. With 11 unique partners across only 2 projects, their consortia are moderately sized and technically diverse. This pattern is consistent with an SME that contributes a defined, differentiated material product to research teams led by academic or larger institutional partners.
Cellendes has worked with 11 unique consortium partners across 9 countries, a notably international reach for a company with only 2 funded projects. This suggests their hydrogel products are already recognized across European research communities, and they are brought in specifically for their material expertise rather than for geographic convenience.
Cellendes occupies a rare niche as a commercial SME that produces research-grade synthetic hydrogel matrices specifically designed for 3D organoid and tissue engineering workflows — a space dominated by academic spin-offs and large life science suppliers. Unlike generic biomaterial vendors, their participation in projects spanning both cell therapy (LSFM4LIFE) and advanced bioprinting (BRIGHTER) demonstrates that their formulations are validated in demanding, grant-funded research contexts. For consortium builders, they offer something scarce: a small company with traceable, peer-validated materials that can be integrated directly into a project's experimental pipeline.
